Phase 3 Endometriosis Trial, Recruiting NCT05862272 Sponsor: Sumitomo Pharma Switzerland GmbH Condition: Endometriosis
Back to Endometriosis

Phase 3 Endometriosis Trial, Recruiting

NCT05862272
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman who has not yet gone through menopause, aged 18 to 50 years old
  • You have been diagnosed with uterine fibroids (confirmed by a scan or medical records) and experience heavy periods that negatively affect your daily life, OR you have been diagnosed with endometriosis that causes moderate to severe pain
  • If there is any chance you could become pregnant, you are willing to use non-hormonal birth control methods for the full 4 years of the treatment period
  • You have a negative pregnancy test at both your screening appointment and your study entry appointment
  • You are in good overall physical and mental health, based on your medical history, physical exams, lab tests, and other assessments
  • Your body weight falls within a healthy range, with a Body Mass Index (BMI) of 18 or above

Who may not be able to join:

  • Your body size or weight exceeds the limits of the bone density scanning equipment used in the trial, or a condition prevents a proper bone density scan of your lower spine or hip
  • Your bone density scan results show that your bones are below a certain level of strength (confirm with trial site for specific values that apply to your situation)
  • Your vitamin D blood level is very low (below 12 ng/mL); note that slightly low levels may still be acceptable if you are already taking or willing to start vitamin D supplements (confirm with trial site)
  • You have, or have had, certain health conditions affecting your bones, hormones, or kidneys — including Cushing's Syndrome, Rheumatoid Arthritis, bone metabolism disorders, untreated overactive parathyroid or thyroid glands, Paget's disease of the bone, Marfan's syndrome, certain forms of Ehlers-Danlos syndrome, kidney disease at stage 3 or above, high prolactin levels, a known pituitary tumour, anorexia nervosa, bulimia (within the last year), or abnormal phosphate levels (some of these may be acceptable if successfully treated — confirm with trial site)
  • You have a history of a bone fracture caused by a minor injury or fall (sometimes called a fragility fracture)
  • You are currently taking or have previously taken medication specifically to treat bone loss (other than calcium or vitamin D supplements)
  • You have used certain hormonal medications for extended periods in the past, including a specific type of injectable contraceptive for more than 2 years within the last 5 years, or certain hormone-blocking treatments for more than 12 months in total (confirm with trial site for exceptions)
  • You have a condition that affects how your body absorbs nutrients, such as inflammatory bowel disease or a history of gastric bypass surgery
  • You currently have breast cancer, have had breast cancer or another hormone-sensitive cancer in the past, are considered at increased risk for such cancers, or are taking medication to treat or prevent breast cancer
  • You have a history of an organ transplant or bone marrow transplant
  • A recent mammogram (within the last 6 months) showed results that require follow-up or further investigation (BIRADS score of 3 or higher — confirm with trial site)
  • You have a known HIV infection or are considered at high risk of contracting HIV
  • You have a current psychiatric condition that, in the opinion of the study doctor, could affect your ability to participate fully or could make it difficult to assess your results
  • You are currently using a hormonal intrauterine device (IUD), hormonal implant, hormonal contraceptive, or other prohibited medication and are not willing to stop using it

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Myovant Medical Director, Myovant Sciences GmbH

Phone: 650-278-8743

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sumitomo Pharma Switzerland GmbH
Registry
ClinicalTrials.gov
Start date
14 August 2023
Est. completion
1 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percent change from baseline in BMD (bone mineral density) at Month 48 on-treatment at lumbar spine (L1-L4) in women with uterine fibroids.; Percent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in women with endometriosis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov